Atlas Trials

A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

Clinical trial NCT05360160 · RECRUITING

Trial details

NCT number
NCT05360160
Sponsor
M.D. Anderson Cancer Center
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Acute Myeloid Leukemia
Start date
2022-10-14
Primary completion
2026-12-01
Enrollment
43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.